PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Byondis and Medac link up to commercialise trastuzumab duocarmazine

Byondis and Medac link up to commercialise trastuzumab duocarmazine.

Byondis and Medac have entered into a license and collaboration agreement for a form of targeted chemotherapy.

Byondis and Medac have announced that they will enter into a license and collaboration agreement to commercialise Byondis’ lead programme anti-HER2 antibody-drug conjugate (ADC), trastuzumab duocarmazine (also known as SYD985).

The treatment is currently pending approval by the European Medicine’s Agency (EMA) and the Medicines and Healthcare products Regulatory Agency (MHRA), as well as other regulatory authorities in Europe.

Under the terms of the agreement, Medac receives an exclusive license to commercialise SYD985 in the EU, the UK and further European countries, in all approved indications.

Trastuzumab duocarmazine incorporates Byondis’ proprietary linker-drug technology, ByonZine. The ADC is comprised of the anti-HER2 monoclonal antibody trastuzumab and a cleavable linker-drug called ‘valine-citrulline-seco-DUocarmycin-hydroxyBenzammide-Azaindole’.

The antibody part of trastuzumab duocarmazine binds to HER2 on the surface of the cancer cell and the ADC is internalised by the cell. After proteolytic cleavage of the linker, the inactive cytotoxin is activated and DNA damage is induced, killing the tumour cells.

SYD985 is considered a form of targeted chemotherapy.

“This collaboration with Medac on SYD985 is a crucial step in ensuring that the therapy, once approved, is available to patients, who desperately need other treatment options,” commented Byondis founder and Chairman Jacques Lemmens.

Byondis CEO Marco Timmers added: “We are pleased to have found in Medac a true partner who shares our passion for innovation and making a difference in the lives of patients,” he added.

“Like Byondis, Medac is committed to developing novel therapies, especially in areas of unmet medical need. We believe in the potential of Byondis and SYD985 and look forward to bringing this next-generation ADC to patients who need it,” concluded Medac managing director, CEO Jörg Hans.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026